Sanofi Aventis, a large cap French pharmaceutical firm developed an effectual weight loss medication, Acomplia. This weight loss medication is to be employed is association with a proper diet plan and regular exercise regime to attain effective results.

Weight loss medication Acomplia is a product of 2 years of clinical trials undertaken in North America. Weight loss is not the only benefit which is sourced by use of this diet pill. Usage of this weight loss medication has also proven to be beneficial in improvement of cardio-metabolic risk factors, smoking cessation, and even minimization of chances of weight gain.

This weight loss medication has been in the news ever since its launch in the year 2006. At present, it is approved for sale in the UK, Switzerland, France, Germany, Ireland, Brazil, Mexico, and even UAE amid other countries.

Although it hasn’t yet received FDA approval for sale in the US but a trade name for its sale in the US Zimulti has already been decided. Sanofi Aventis is hopeful about its approval in the future, for which a fresh 50-month trials are already on their way, estimated to be completed in the year 2010. It seems that it would be until these trials are completed that the FDA would reconsider its decision on usage of this diet pill in the US.

It works upon the mechanism of appetite suppressant, and in this way beneficial in weight loss. Excessive desire to eat is the prime reason for weight gain, a medication which could reduce this urge can effectively facilitate trimming down of your body shape. Use of this medication is suggested to be employed with a proper diet plan and regular exercise plan for attainment of desired results.

Usage of this medication is intended for individuals with a BMI 30; or BMI 27 along with obesity related risk factors such as high cholesterol or type 2 diabetes. In order to ascertain the suitability of the medication, speak with your general practitioner before initiating this weight loss medication.